People often stop GLP‑1s
An NPR report finds a majority of people who start GLP‑1 drugs later quit and plan to restart them, even though cycling on and off these medications is not recommended. (npr.org) The April 15 piece highlights that the health effects of that start‑stop pattern remain unclear. (npr.org)
Glucagon-like peptide-1 drugs work by dialing down hunger and slowing how fast food leaves the stomach, and many patients do not stay on them continuously. An NPR report published April 15 found that most people who start these drugs later stop, and many of those former users say they expect to start again. (ijpr.org) The pattern spans medicines sold as Wegovy, Ozempic, Zepbound, and Mounjaro, which are used for obesity, type 2 diabetes, or both. Leigh O'Donnell of the market research firm Kantar told NPR that 74% of people who had lapsed said they were likely or very likely to return to a glucagon-like peptide-1 drug. (iowapublicradio.org) Doctors generally prescribe these medicines as long-term treatment, not as a short course to finish and revisit later. The Food and Drug Administration labels for Wegovy and Zepbound say the drugs are used with diet and exercise to reduce excess body weight and maintain weight reduction long term. (accessdata.fda.gov, accessdata.fda.gov) That long-term framing has collided with real-world dropout rates. A November 2024 JAMA commentary said real-world estimates put glucagon-like peptide-1 receptor agonist discontinuation at 50% to 75% by 12 months, even as the drugs are intended for chronic obesity and diabetes management. (jamanetwork.com) Cost and coverage are a major reason people stop. KFF Health News reported in January that some older adults lost access when insurance stopped paying, and one patient quoted in the story had gone from a $25 monthly copay to a price above $1,000 a month out of pocket. (kffhealthnews.org) Side effects also push people off treatment. The same JAMA commentary said patients often discontinue after gastrointestinal problems, while Cleveland Clinic researchers said cost or insurance limits and side effects were the two main drivers they had documented, with cost the bigger one. (jamanetwork.com, newsroom.clevelandclinic.org) Clinical trials have shown what often happens after stopping. In the STEP 1 extension, people who discontinued semaglutide regained about two-thirds of their prior weight loss within a year, and cardiometabolic measures moved back toward baseline. (pmc.ncbi.nlm.nih.gov) Tirzepatide data point the same way. A post hoc analysis of the SURMOUNT-4 trial, published in JAMA Internal Medicine, found that people who withdrew from tirzepatide and regained at least 25% of lost weight also saw greater reversal of improvements in blood pressure, cholesterol, blood sugar, and insulin resistance. (jamanetwork.com) Real-world care can look messier than a trial, because many patients restart treatment or switch to another drug. Cleveland Clinic said its March 12 analysis of 7,938 adults found 55% of patients in the obesity group gained weight in the year after stopping, while 45% stayed the same or kept losing, a result the researchers linked in part to restarting medication or moving to another treatment. (newsroom.clevelandclinic.org) What remains unsettled is the health effect of repeatedly stopping and restarting. NPR reported that researchers do not yet know the long-term consequences of that cycle, even as more patients move in and out of treatment because of price, supply, side effects, and changing insurance rules. (nprillinois.org)
